Memo Therapeutics

Schlieren, Switzerland

Memo Therapeutics is a biotechnology research company that engages in antibody discovery and immune repertoire analysis.

May 2024

Series C

Biotechnology Collaboration Health Care Medical

Top Investors

Schroders CapitalKurma PartnersYsios CapitalVerve Venturesredalpine

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Memo Therapeutics

Who are Memo Therapeutics's investors?

Memo Therapeutics's investors include Schroders Capital, Kurma Partners, Ysios Capital, Verve Ventures, redalpine.

Where is Memo Therapeutics headquartered?

Memo Therapeutics is headquartered in Schlieren, Switzerland.

What does Memo Therapeutics do?

Memo Therapeutics is a biotechnology research company that engages in antibody discovery and immune repertoire analysis.

What stage is Memo Therapeutics at?

Memo Therapeutics is at the Series C stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated May 7, 2024.

MLA

"Memo Therapeutics — Funding & Investors." VCBacked, May 7, 2024, https://www.vcbacked.co/company/memo-therapeutics. Accessed July 1, 2026.

APA

VCBacked. (2024). Memo Therapeutics — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/memo-therapeutics

Wikipedia (cite web)

{{cite web |title=Memo Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/memo-therapeutics |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated May 7, 2024.

Similar Companies in Biotechnology

View all

Renaissance BioScience

Vancouver

Rapport Therapeutics

Boston

Neuroglee Therapeutics

Singapore

Living In Silico Inc.